Brief: Matinas Biopharma Holdings Reports Q1 Loss Per Share Of $0.04

Matinas BioPharma Holdings

14/05/2019 12:09

May 14 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA PROVIDES CORPORATE UPDATE AND REPORTS
FIRST
QUARTER 2019 FINANCIAL RESULTS
    * Q1 LOSS PER SHARE $0.04
    * PLANS TO COMMENCE A CLINICAL BIOAVAILABILITY STUDY AND
COMPARISON OF PK PARAMETERS FOR MAT9001 IN Q3 2019.
    * PLANS TO COMMENCE 28-DAY COMPARATIVE BRIDGING TOXICOLOGY
STUDY
OF MAT9001 IN Q2 2019
    * ENDED QUARTER WITH CASH AND CASH EQUIVALENTS OF
APPROXIMATELY
$39.4 MILLION.

Source text for Eikon:  ID:nGNX5Lw43R 
Further company coverage:  MTNB.A 

 ((Reuters.Briefs@thomsonreuters.com;))